X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.


Latest Post

May 02, 2019

FDA Guidance Affecting cGMP Compounding Pharmacies (503Bs)

Since the 2012 New England Compounding Center tragedy that linked a deadly fungal meningitis outbreak to a failure to use current good manufacturing practices (cGMP),<sup>1</sup> compounding pharmacies have faced increasing scrutiny and regulation by the U.S. Food and Drug Administration (FDA). While registering with the FDA is still voluntary, only compounding pharmacies that register, and pass inspection, will be granted “503B” status as compounding outsourcing facilities under Section 503B of the Federal Food, Drug, and Cosmetic Act.<sup>2</sup>
Amy Kim

Amy Kim

Sr. Specialist, Scientific Communications, SA & TS

Previous Posts
SmartDose Platform

April 26, 2019

Overcoming Challenges Associated with Biologic Drug Formulation and Development

Victoria Morgan

Victoria Morgan

Director, Segment Marketing, Global Biologics

Introducing Integrated Solutions

October 08, 2018

Introducing Integrated Solutions

Deirdre Swinden

Deirdre Swinden

Director, Marketing Communications

The SmartDose Platform in use

August 10, 2018

Combination Products - Why Design Verification Studies Are Needed

Daniel Bantz

Daniel Bantz

Technical Manager, Packaging & Performance, Lab

Load more